The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether Latuda (lurasidone), from...
This post hoc analysis of a double blind (DB), randomized, placebo, controlled, relapse?
Cariprazine is a new dopamine D2 and D3 receptor partial agonist antipsychotic.
The purpose of this review is to describe the available data for brexpiprazole in the maintenance treatment of schizophrenia.
Cariprazine (Vraylar™) is a dopamine D3-preferring D2/D3 receptor partial agonist indicated for the treatment of patients with schizophrenia.
The dopamine hypothesis suggests that dopamine abnormalities underlie psychosis, irrespective of diagnosis, implicating dopamine dysregulation in bipolar affective disorder and schizophrenia...